Quince Therapeutics, Inc.
QNCX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $18,590 | $9,447 | $25,178 | $60,795 |
| G&A Expenses | $17,580 | $17,695 | $26,012 | $29,523 |
| SG&A Expenses | $17,580 | $17,695 | $26,012 | $29,523 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $21,115 | $7,478 | $825 | $0 |
| Operating Expenses | $57,285 | $34,620 | $52,015 | $90,318 |
| Operating Income | -$57,285 | -$34,620 | -$52,015 | -$90,318 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $544 | $3,038 | $71 | $373 |
| Pre-Tax Income | -$56,741 | -$31,582 | -$51,944 | -$89,945 |
| Tax Expense | $87 | -$197 | -$284 | $0 |
| Net Income | -$56,828 | -$31,385 | -$51,660 | -$89,945 |
| % Margin | – | – | – | – |
| EPS | -1.31 | -0.84 | -1.54 | -3.03 |
| % Growth | -56% | 45.5% | 49.2% | – |
| EPS Diluted | -1.31 | -0.84 | -1.54 | -3.03 |
| Weighted Avg Shares Out | 43,262 | 37,237 | 33,497 | 29,719 |
| Weighted Avg Shares Out Dil | 43,262 | 37,237 | 33,497 | 29,719 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,929 | $3,478 | $1,068 | $620 |
| Interest Expense | $0 | $0 | $568 | $0 |
| Depreciation & Amortization | $186 | $322 | $204 | $344 |
| EBITDA | -$35,984 | -$26,820 | -$50,986 | -$89,974 |
| % Margin | – | – | – | – |